Accutane (Isotretinoin) Medicaid Coverage by State Tier: 2026 Guide

Does the isotretinoin label say which Medicaid tier it sits on?

No. The Absorica prescribing information covers the indication, dosing, warnings and the iPLEDGE REMS; it does not describe Medicaid tier placement [1]. Tier and coverage requirements are found in your Medicaid plan's current formulary for the exact isotretinoin product.

What the labeling does fix is the set of distribution rules that any prescription must satisfy.

What the label fixes

Isotretinoin capsules are FDA-approved only for severe recalcitrant nodular acne, meaning multiple inflammatory nodules 5 mm or larger, in non-pregnant patients 12 and older who have not responded to conventional therapy including systemic antibiotics [1]. Absorica is dosed at 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks; Absorica LD is dosed at 0.4 to 0.8 mg/kg/day over the same period. Adults with very severe disease with scarring or trunk involvement may go up to 2 mg/kg/day of Absorica (1.6 mg/kg/day of Absorica LD) as tolerated; once-daily dosing is not recommended [1]. The label says a second course is not recommended before a 2-month wait [1].

Under the iPLEDGE REMS, pharmacies dispense a maximum 30-day supply with a Medication Guide and no refills, and a further supply requires a new prescription and a new iPLEDGE authorization [1][4].

The iPLEDGE steps that drive timing and repeat fills

For patients who can get pregnant, the label describes a screening pregnancy test in a medical setting, then a confirmatory test in a medical setting at least 30 days later and after at least 30 days of the chosen pregnancy prevention, which is two forms of contraception or committed abstinence [1]. During treatment the label requires a pregnancy test within 7 days before each prescription, and testing continues after treatment [1]. The label says breastfeeding is not recommended during treatment and for at least 8 days after the last dose [1]. Patients who cannot get pregnant are enrolled too, and must not share the drug or donate blood [1].

FDA approved modifications to the REMS on 2026-02-09. They include prescriber-permitted home pregnancy tests during and after treatment (pre-treatment tests must still be done in a medical setting) and no waiting period for a repeat test after a missed 7-day window. FDA's page gives 2026-11-15 as the planned implementation date, delayed from 2026-08-08 [5][2]. The Absorica label already includes home-test language [1].

Which capsule product to look up

Absorica and Absorica LD are not substitutable mg for mg because their bioavailability and recommended doses differ [1]. Absorica may be taken with or without meals, while the older-format isotretinoin labels (Accutane-type) say to take the drug with food because fasting significantly decreases absorption [1][4]. Because of these differences, a plan formulary check should name the exact product.